ArticleChemSusChem2025
Synthesis of 19-Hydroxyarachidonic Acid by Fungal Peroxygenases: An Experimental and Computational Study.
Article in ChemSusChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hydroxylated derivatives of arachidonic acid play crucial roles in physiology and inflammation response, with distinct biological effects for (R)- and (S)-enantiomers, highlighting their pharmaceutical relevance. Here, recombinant unspecific peroxygenases (UPOs) are harnessed-from the fungi Coprinopsis cinerea (rCciUPO) and Agrocybe aegerita (rAaeUPO), and the rAaeUPO engineered variants A77L, A77T, and A77N-to regio- and enantio-selectively hydroxylate arachidonic acid. rCciUPO and rAaeUPO primarily produced ω-1 and ω-2 hydroxy derivatives, with certain overoxidation to keto forms, while the rAaeUPO variants show enhanced regioselectivity to ω-1 hydroxylation and minor overoxidation. Remarkably, A77L exhibited very good enantioselectivity, yielding 92% of the (S)-enantiomer of 19-hydroxyarachidonic acid. Molecular dynamics simulations revealed that the narrowing of the active-site channel by the A77L mutation imposes critical torsional constraints on the substrate, favoring selective hydroxylation and preventing overoxidation of hydroxylated products. In this way, key interactions involving residues T242, E245, and D70 modulate enantioselectivity by interacting with the substrate's carboxylate moiety. Additional experimental assays show that these UPOs efficiently hydroxylate other bioactive C18-C22 fatty acids. The experimental and computational data integration findings provide a rational basis for engineering UPO selectivity, presenting the enzyme variant A77L as a promising biocatalyst for the selective synthesis of pharmacologically relevant hydroxy-fatty acids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.